Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of up-front chemotherapy and neoadjuvant short-course radiotherapy for resectable rectal carcinoma
2013-000770-30Phase 2Completed
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Mar 2013
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, fluorouracil and levoleucovorin in rectal cancer and rectal adenocarcinoma, sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoint: Safety of radiotherapy treatment (Step A). Started Mar 2013; status: completed.
02
Drugs
oxaliplatinfluorouracillevoleucovorin
03
Conditions
rectal cancerrectal adenocarcinoma
Beyond the preview
Go deeper on 2013-000770-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000770-30.